Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Diaphragmatic Mobility, Lung Hyperinflation and Effects of the Pulmonary Rehabilitation
To determine whether the COPD impairs the diaphragmatic mobility (DM), and verify
improvements after an inpatient pulmonary rehabilitation (PR).
Ultrasonography on M-mode will assess the diaphragmatic mobility at rest breathing and at
slow deep inspiration. Lung functions test, arterial blood gas analyses, six minute walk test
will be also performed, on COPD patients and healthy subjects.
The diaphragm pathophysiological changes occurring in chronic obstructive pulmonary disease
(COPD) leads to functional inefficiency that strongly correlates to the loss of lung
function. Muscle fiber shortening follows lung hyperinflation, resulting to a chronic
mechanical disadvantage, which worsens in COPD exacerbations. The DM is mostly assessed with
techniques that exposes the patient to risks. The ultrasonography on M-mode is easy to use,
safe and measures directly the diaphragmatic dome displacement. The study aim to determine
whether the COPD impairs the DM, and verify improvements after an inpatient PR.
Every COPD patient will comprise a standard evaluation that consists on lung function test,
six minute walk test and arterial blood gas analyses, according to the American Thoracic
Society/ European Respiratory Society (ATS/ERS) statements.
Within the second day of recovery the diaphragm mobility ultrasonographic (US) measurement
will be assessed as follow: the patients positioned in a semi recumbent position (45
degrees).The US probe positioned between the anterior and mean axillary line, on the central
right subcostal area, cranial and dorsal. The US wave perpendicularly on the posterior
hemidiaphragm third (it is visualized as the hyperechogenic line behind the liver). The
mobility assessed by M-mode while the patient breaths on tidal volume (rest breathing) and
deep slow breathing (to Functional Residual Capacity).
The COPD patients classification and diagnosis will be according to the the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria. Every patient, after the assessment
will follow the PR as ATS/ERS statement on pulmonary rehabilitation. All patients will follow
a routine of five days a week of physical exercise. The rehabilitation program consists on a
30 minutes calisthenic gymnastic once a day, 20 minutes of cycloergometer training activity
twice a day. The aerobic cycloergometer training was set at 60%-70% of the maximum cardiac
frequency determined by 220 minus the patients age. The patients will perform lower limbs
strengths exercises, especially for the quadriceps and hamstring. During the in-hospital
stay, the patients will receive regular prescribed medication and oxygen therapy according to
the medical staff evaluation, which will be prescribed by the clinician in charge. The
patients will also have respiratory physiotherapy, regarding the presence of lung secretion
retain, and the need to expand unventilated areas.
The control group will be composed by healthy volunteers. The volunteers will be screened on
their lung function. The subjects on the control group will be submitted to the same
evaluation protocol regarding the spirometry and the M-mode ultrasonography.
Statistical analyses:
The qualitative description of the data will be made with percentages and frequency. The
quantitative data described as means and standard deviation for the symmetrical
distributions. The Kolmogorov-Smirnov test to determine distributions mean normality. A
One-way analysis of variance (ANOVA) with repeated measurements and Bonferroni test will be
used as post-hoc test to evaluate statistical significance. Within-group effect sizes will be
calculated using the Cohen d coefficient interpretation. For all the study data, the P values
lower than 0.05 will be consider significant. The investigators will use the Student T- test
for independent sample for quantitative data and for comparisons between the COPD patients
and control group and ANOVA to the comparisons within COPD group. The investigators will use
Pearson's correlation test to measure the correlation between the diaphragmatic mobility and
the lung functioning variables.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|